Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today is celebrating the first shipment and patient dosing from its second manufacturing facility for the production of its ²⁰³Pb- and ²¹²Pb-labeled radiopharmaceuticals.

Located in Somerset, New Jersey, this facility is now operational to supply investigational products to support VMT-α-NET clinical studies, in addition to the Coralville, Iowa facility which has been producing the Company's investigational products for over 15 months. With three manufacturing suites that can meet Current Good Manufacturing Practice (cGMP) requirements, the Somerset facility is expected to have the capacity to meet future clinical trial and commercial demands at major cancer treatment centers throughout the Northeastern U.S. Until the close of its acquisition by Perspective in March 2024, this facility was operated by Lantheus Holdings, Inc., the leading radiopharmaceutical-focused company. This facility previously produced Azedra, which contained a form of radioactive iodine and received approval from the U.S. Food & Drug Administration (FDA) in 2018 for the treatment of rare tumors of the adrenal gland.

"Today marks an exciting milestone as we start shipping investigational products from this state-of-the-art facility," commented Shane Cobb, Perspective's Executive Vice President of Operations. "Going operational seven months after taking possession of the facility allows us to accelerate our efforts in delivering investigational products and, pending approval, new radiopharmaceutical therapies."

"We are thrilled to celebrate the opening of this facility, which is a step forward in building out our manufacturing and supply chain capabilities," said Thijs Spoor, Perspective's Chief Executive Officer. "It reflects our commitment to delivering targeted alpha-particle therapies to patients in critical need. We believe our network approach aligns with patient interest and the half-life profiles of isotopes contained in our investigational products. We look forward to replicating this effort and adding sites strategically to enhance our network to support key treatment hubs across the U.S."

About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc., is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha emitting isotope ²¹²Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides. The Company is also developing complementary imaging diagnostics that incorporate the same targeting peptides which provide the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity.

The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-α-NET) programs have entered Phase 1/2a imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several leading academic institutions. The Company has also developed a proprietary ²¹²Pb generator to secure key isotopes for clinical trial and commercial operations.

For more information, please visit the Company's website at www.perspectivetherapeutics.com.